Related Experiment Video
Updated: Jun 21, 2026
A Preclinical Controlled Cortical Impact Model for Traumatic Hemorrhage Contusion and Neuroinflammation
Published on: June 10, 2020
Modern approaches to pediatric brain injury therapy
Peter A Walker1, Matthew T Harting, James E Baumgartner
1Department of Pediatric Surgery, University of Texas Medical School at Houston, Texas 77030, USA.
Insights
Pediatric traumatic brain injury (TBI) causes significant morbidity and mortality. Research explores progenitor cells, hypertonic saline, and hypothermia as potential multimodality treatments for TBI.
Area of Science:
- Neuroscience
- Pediatric Medicine
- Trauma Surgery
Background:
- Pediatric traumatic brain injury (TBI) leads to over 435,000 emergency visits annually in the US.
- TBI involves immediate mechanical damage and secondary biochemical/inflammatory injury cascades.
- Current pharmacologic monotherapies have failed in phase III trials.
Purpose of the Study:
- To review the complex pathophysiology of pediatric TBI.
- To explore potential therapeutic mechanisms of progenitor cell transplantation, hypertonic saline infusion, and controlled hypothermia.
- To inform the development of multimodality treatments for TBI.
Main Methods:
- Review of preclinical and clinical research on TBI.
- Analysis of the mechanisms of action for progenitor cell therapeutics.
- Evaluation of hypertonic saline infusion and controlled hypothermia as TBI interventions.
Main Results:
- TBI pathophysiology involves primary mechanical injury and secondary inflammatory responses.
- Progenitor cell therapy, hypertonic saline, and hypothermia show preliminary promise.
- Existing phase III trials for pharmacologic monotherapy in TBI have yielded negative results.
Conclusions:
- Multimodality treatment strategies are recommended for TBI based on NIH consensus.
- Progenitor cell transplantation, hypertonic saline, and controlled hypothermia warrant further investigation in clinical trials.
- Understanding TBI pathophysiology is crucial for developing effective multimodality therapies.
Abstract:
Each year, pediatric traumatic brain injury (TBI) accounts for 435,000 emergency department visits, 37,000 hospital admissions, and approximately 2,500 deaths in the United States. TBI results in immediate injury from direct mechanical force and shear. Secondary injury results from the release of biochemical or inflammatory factors that alter the loco-regional milieu in the acute, subacute, and delayed intervals after a mechanical insult. Preliminary preclinical and clinical research is underway to evaluate the benefit from progenitor cell therapeutics, hypertonic saline infusion, and controlled hypothermia. However, all phase III clinical trials investigating pharmacologic monotherapy for TBI have shown no benefit. A recent National Institutes of Health consensus statement recommends research into multimodality treatments for TBI. This article will review the complex pathophysiology of TBI as well as the possible therapeutic mechanisms of progenitor cell transplantation, hypertonic saline infusion, and controlled hypothermia for possible utilization in multimodality clinical trials.
